183 related articles for article (PubMed ID: 11036840)
1. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
Adachi JD; Roux C; Pitt PI; Cooper C; Moniz C; Dequeker J; Ioannidis G; Cawley MI; Jenkins EA; Walker-Bone KE; Pack S; Stephenson GF; Laan RF; Brown J; Geusens P
J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
[TBL] [Abstract][Full Text] [Related]
2. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
Adachi JD; Bensen WG; Brown J; Hanley D; Hodsman A; Josse R; Kendler DL; Lentle B; Olszynski W; Ste-Marie LG; Tenenhouse A; Chines AA
N Engl J Med; 1997 Aug; 337(6):382-7. PubMed ID: 9241127
[TBL] [Abstract][Full Text] [Related]
3. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
Sato S; Ohosone Y; Suwa A; Yasuoka H; Nojima T; Fujii T; Kuwana M; Nakamura K; Mimori T; Hirakata M
J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
[TBL] [Abstract][Full Text] [Related]
4. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
[TBL] [Abstract][Full Text] [Related]
5. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
Adachi J; Cranney A; Goldsmith CH; Bensen WG; Bianchi F; Cividino A; Craig GL; Kaminska E; Sebaldt RJ; Papaioannou A
J Rheumatol; 1994 Oct; 21(10):1922-6. PubMed ID: 7837160
[TBL] [Abstract][Full Text] [Related]
6. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
Sebaldt RJ; Ioannidis G; Adachi JD; Bensen WG; Bianchi F; Cividino A; Gordon M; Kaminska E; Scocchia T; Petrie A; Stephenson GF; Goldsmith CH
J Rheumatol; 1999 Jul; 26(7):1545-9. PubMed ID: 10405943
[TBL] [Abstract][Full Text] [Related]
7. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
Sato S; Takada T; Katsuki Y; Kimura N; Kaneko Y; Suwa A; Hirakata M; Kuwana M
J Rheumatol; 2008 Jan; 35(1):142-6. PubMed ID: 18050368
[TBL] [Abstract][Full Text] [Related]
8. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
9. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
11. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
Buckley LM; Hillner BE
J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
Roux C; Oriente P; Laan R; Hughes RA; Ittner J; Goemaere S; Di Munno O; Pouillès JM; Horlait S; Cortet B
J Clin Endocrinol Metab; 1998 Apr; 83(4):1128-33. PubMed ID: 9543129
[TBL] [Abstract][Full Text] [Related]
13. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
[TBL] [Abstract][Full Text] [Related]
14. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
Saag KG; Emkey R; Schnitzer TJ; Brown JP; Hawkins F; Goemaere S; Thamsborg G; Liberman UA; Delmas PD; Malice MP; Czachur M; Daifotis AG
N Engl J Med; 1998 Jul; 339(5):292-9. PubMed ID: 9682041
[TBL] [Abstract][Full Text] [Related]
15. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
Bolanca S; Korsić M; Dekanić D; Cvijetić S
Acta Med Croatica; 1998; 52(3):159-63. PubMed ID: 9818438
[TBL] [Abstract][Full Text] [Related]
16. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
17. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
Geusens P; Dequeker J; Vanhoof J; Stalmans R; Boonen S; Joly J; Nijs J; Raus J
Ann Rheum Dis; 1998 Dec; 57(12):724-7. PubMed ID: 10070271
[TBL] [Abstract][Full Text] [Related]
18. Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy.
Skingle SJ; Moore DJ; Crisp AJ
Int J Clin Pract; 1997 Sep; 51(6):364-7. PubMed ID: 9489064
[TBL] [Abstract][Full Text] [Related]
19. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
[TBL] [Abstract][Full Text] [Related]
20. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Cohen S; Levy RM; Keller M; Boling E; Emkey RD; Greenwald M; Zizic TM; Wallach S; Sewell KL; Lukert BP; Axelrod DW; Chines AA
Arthritis Rheum; 1999 Nov; 42(11):2309-18. PubMed ID: 10555025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
